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What can we predict for 2020? Solar and lunar eclipses? Without a doubt. 
Climate change? Most likely. Rising sea levels? Signs point to yes. Beyond 
that, however, in the world of human events, it is best to be cautious. In the 
field of health and medicine (or anywhere else, for that matter), no one 
predicted the most important discoveries of the twentieth century. Economists 
were no more successful in foreseeing financial or economic crises. The 
pundits did not forecast any of the recent wars, disruptions or even the recent 
Arab Spring movements—indeed, political experts turned out to be only 
slightly more accurate than dart-throwing chimpanzees in divining what was 
in store for the future.1 As the World Health Organization (WHO) and the 
wider scientific community looked to East Asia in anticipation of the next 
outbreak of H5N1, the influenza H1N1 pandemic took hold in Mexico. 
Tsunamis, volcanic eruptions, earthquakes, drug scandals, outbreaks of 
emerging diseases and political disruptions are notoriously unpredictable, as 
Nassim Nicholas Taleb brilliantly highlighted in his book TheBlackSwan.2
Under these circumstances, where change is the only constant, Peter 
Drucker used to say that we have to prepare for “the future that has already 
happened”,3 that is, we must examine our present to glean clues about our 
future. When Charles Townes’s research on light diffraction led to the 
invention of the laser, he could not foresee the thousands of applications it 
would have in the field of home video and music, nor the major impact in eye 
surgery and medicine. But innovative scientists and engineers transformed it 
into a tremendously beneficial tool for humankind by envisaging the potential 
fruit of a tree whose seed had only just been planted. 
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Policymakers and public health professionals are thusly charged with 
preparing health systems and populations for future challenges as best as 
possible, relying upon the knowledge available to us now. There are some 
weighty trends whose mechanisms have already been set into motion; these 
will to a great extent shape our future. Demographic trends within populations 
and workforces, current prevalence of important disease determinants 
(obesity, smoking)... these are fundamentally reliable indicators that we can 
use to plan for appropriate health system responses. While we cannot shut 
the door on the surprises that the future holds, it is highly probable that up to 
2030, cancers, coronary heart diseases and stroke will remain, the three 
primary causes of mortality in developed countries.4 It is also foreseeable 
that unipolar depression, diabetes and dementias will become the foremost 
causes of burden of diseases in these settings.4
Beyond those trends, it is difficult to predict the breakthroughs that will 
change people’s lives and revolutionize how we deal with disease. A few 
months ago, we might have imagined that stenting would dramatically 
change the prognosis of stroke in intracranial stenosis. Yet, a 450-patient 
randomized trial was stopped early due to increased mortality one year 
after treatment in the intervention arm.5 It is hard to anticipate if 
mammography will remain the gold standard for early detection of breast 
cancer due to emerging doubts and controversy raised about its true 
efficacy.6 By contrast, early detection of lung cancer with spiral low dose 
tomodensitometry may be recommended in the near future, after the 
publication of a large NIH-funded clinical trial involving more than 50,000 
heavy smokers or former heavy smokers aged 55 to 74.7 This trial was also 
terminated early, but in this case it was due to a significant decrease in all 
causes mortality, as well as in lung cancer specific mortality. Promising 
breakthroughs against two of the scourges of the developing world, malaria8 
and HIV/AIDS,9 could also dramatically change the global disease burden. 
Other new developments will increase the demand for new skills and 
competencies in public health agencies. In drug safety, for example, computer 
assisted data mining may progressively replace old clinical or pharmaceutical 
assessment of side effects. A team from Harvard recently developed a tool 
using big data approaches, which combined data mining with mathematical 
and statistical modeling to explore the potential for forecasting adverse 
effects.10 A validation sample showed that their models would have been 
powerful in making such predictions, which could help pharmaceutical 
industries and health authorities to prevent disasters in drug safety.
We can only speculate on which country will rank first in tobacco 
control. Sweden, whose tough anti-tobacco policies include smoking bans 
in public settings, increases in cigarette tax, and warnings on package 
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labeling, paradoxically has one of the highest levels of oral tobacco use in 
OECD countries. This use of smokeless tobacco, although not well assessed, 
probably has a much lower impact on health than smoking tobacco, with 
possibly no propensity to lead to cancer or cardiovascular disease. This 
form of consumption, as well as others such as electronic cigarettes, will 
likely result in changes to the smoking-related disease pattern in the future; 
however, what those changes will be is a question still open to debate.
In 2020, genomics and genetics will probably have led to further 
progress. To what extent they will impact public health remains to be seen, 
but a new discipline known as “public health genomics” is emerging to 
explore the potential. Today, online services are offering tests to detect rare 
genetic diseases (e.g., more than 150 tests on a chip), which are already 
being reimbursed by health plans in the United States. It is still premature 
to speculate that this type of testing will become routine in the future, but it 
is undoubtedly a topical public health issue, with possibly serious ethical 
and legal implications.
In the same line of reasoning, nanotechnologies are also growing 
quickly in the field of health and medicine, with tremendous promise for 
human health. Today, pancreatic cancer is among the tumors whose 
prognosis is the most grim, but tomorrow, the novel, low-cost application 
of carbon nanotubes to detect mesothelin biomarkers developed by 15 year-
old Jack Andraka could conceivably bring survival rates in line with those 
seen in breast cancers.11 Patients with chronic disease, such as type II 
diabetes, may also stand to benefit, and public health surveillance and 
monitoring could be substantially improved. 
Just as important to consider as what the benefits of all these new 
technologies will be, is how to guarantee their universal access when proven 
effective. Patient empowerment, globalization, the spread of democracy, 
mobile technology and the internet are all factors that contribute to the 
breakdown of the status quo, and it is no longer tolerable to imagine that 
only a privileged few will be able to screen against disease, benefit from the 
best surveillance, or have access to high tech devices for their health. 
Citizens increasingly occupy—rightfully so—centre stage in the health 
system, and they will be crucial to guaranteeing the quality and legitimacy 
of any public health plan. In the United States, the Patient Protection and 
Affordable Care Act has led to the creation of the Patient-Centered Outcome 
Research Institute (PCORI), funded by US$1 billion from the federal 
budget; the organization is charged with performing comparative clinical 
effectiveness research in close association with patients’ associations. 
Elsewhere, the influence of social networks and NGOs is also growing, 
entailing a tremendous impact on political decisions, transparency and 
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accountability issues, and participation in formulating innovative measures 
to collectively improve health through longer and better-quality lives.
All of the above considerations pose considerable challenges to the 
question of how we can best equip our health systems to respond to the 
known and unknown threats to future health. Money is certainly an issue, 
but, as Avedis Donabedian wrote, there is a “point of optimality”,12 after 
which investment of resources may not be associated with an increase in 
population net benefit, due to continuous and linear increase in population 
harm. The exact coordinates of this point of optimality is far from clear in 
most instances, but we can surmise that health system performance is just 
as important as the financing that enables it to function.
Despite all the enigmas shrouding the future, health systems do not have 
the luxury of improvisation: It takes years, if not decades, to roll out programs 
that are sufficiently funded, staffed and equipped, requiring health systems 
to be proactive in their preparations. Planners must consider the current and 
future disease burden (almost certain to be dominated by chronic illness), 
potential but unpredictable threats such as infectious disease outbreaks, and 
emerging tools that can aid public health pract itioners. Plans must also 
contextualize the health system within other social and economic trends: the 
(ongoing) financial crisis, the communication revolution, technological 
innovation, and the horizontalization of govern ment policy. In fact, con-
ventional wisdom has come to accept the fact that health outcomes greatly 
depend on disease determinants that originate in multiple sectors of society, 
not just in the health system. Effective health promotion and protection will 
only be possible through intersectoral action, leading to a paradigm shift in 
which governance for health (rather than health governance) emerges as the 
most comprehensive and effective way to realize a true whole-of-government/
whole-of society approach. Only with these complex considerations in mind 
can countries begin to develop strategies for the future, and these must then 
be capable of adapting quickly to unfolding events.
This thematic issue will examine several countries that have developed 
plans for 2020, including the American HealthyPeople2020 and Healthy
Israel 2020. These two countries illustrate the differences—but also the 
similarities—between diverse health systems and the approaches they take 
towards preparing for the future. The goals are obviously the same: 
anticipating future trends and needs as well as proposing targets to reach. 
But their methods are notably different. 
The United States is more familiar with this exercise, since as early as 
1979, there have been national goals in public health, with successive ten-
year plans at a federal level since 1990. Success of past policy has been 
mixed. In 2010, for example, the objective related to prevalence of type II 
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diabetes (below 3.8 cases per 1,000 adults) was not reached, remaining 
above 8.0, while the target for mortality due to coronary heart disease was 
attained by 2004, and the trend was still favorable and better than anticipated 
six years later. In the ongoing plan covering the decade 2011–2020, there 
are 12 priorities, with 26 indicators drawn from a catalogue of 600 
objectives according to 42 domains and including more than 1,200 inter-
vention measures. This new plan represents a real attempt to prioritize 
public health intervention at a federal level, including a wide range of 
topics such as environmental health, mental health, oral health, and social 
determinants of health. Targets are clearly defined and measurable. 
On the other side of the world, Israel has proposed a truly innovative 
approach with HealthyIsrael2020. The plan’s 30 actions include promoting 
physical activity, preventing alcohol-related diseases and promoting mental 
health. Like plans from other countries, it also includes a number of targets; 
however, unlike its counterparts, a method for how to reach them is also 
delineated. Integrated approaches for the proposed strategies and inter-
ventions have been formulated and adopted, involving local authorities, 
communities, employers, educators, media and social marketing activists, 
healthcare professionals and legislators, as well as supportive measures to 
monitor and evaluate progress. All proposals were carefully and extensively 
documented against available international evidence in order to elaborate 
something truly elusive and far too singular: real evidence-based policy. 
PublicHealthReviews is proud to dedicate this thematic issue to the 
future of public health in the United States, Europe, and the world, shedding 
light on the complex factors that will feed into heath system responses and 
highlighting a number of splendid initiatives underway across the globe. We 
hope that the critical assessments (and the occasional disagreements) from 
experts and researchers who rank among the best in these fields will aid in 
our collective understanding of how to best achieve agile, resourceful health 
systems capable of protecting and improving health for all populations.
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